Publicacións nas que colabora con María Díez Campelo (10)

2024

  1. Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia

    Biomarker Research

2022

  1. Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells

    Therapeutic Advances in Hematology, Vol. 13

2018

  1. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

    Blood cancer journal, Vol. 8, Núm. 12, pp. 117

2016

  1. Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients

    PLoS ONE, Vol. 11, Núm. 2

2015

  1. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II panobidara study

    Haematologica, Vol. 100, Núm. 10, pp. 1294-1300

2014

  1. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome

    Leukemia Research, Vol. 38, Núm. 5, pp. 551-556

2012

  1. Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients

    Haematologica, Vol. 97, Núm. 8, pp. 1218-1224

2009

  1. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies

    American Journal of Hematology, Vol. 84, Núm. 3, pp. 149-152

2008

  1. Clinical and prognostic value of discrepancies in microsatellite dna regions between recipient and donor in human leukocyte antigen-identical allogeneic transplantation setting

    Transplantation, Vol. 86, Núm. 7, pp. 983-990

2002

  1. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation

    Leukemia, Vol. 16, Núm. 8, pp. 1423-1431